Imidazoline binding sites and signal transduction pathways

Area of Science:

• Pharmacology
• Neuroscience
• Cardiovascular Physiology

Background:

• Discrete non-adrenergic imidazoline binding sites (I1 and I2) exist in the brain and periphery.
• The I1 site, prevalent in the brainstem, is implicated in blood pressure regulation via hypotension.
• The precise signaling pathway for I1 imidazoline site action remains unclear.

Purpose of the Study:

• To investigate the non-adrenergic mechanism by which imidazolines modulate nicotine-stimulated responses in PC-12 cells.
• To determine if imidazoline action involves protein kinases or G-proteins.
• To elucidate the molecular target of imidazolines like clonidine and cirazoline.

Main Methods:

• Utilized rat phaeochromocytoma (PC-12) cells to assess nicotine-stimulated calcium entry and inward currents.
• Examined the effects of imidazolines (clonidine, cirazoline) on these cellular responses.
• Investigated the role of protein kinases and G-proteins using specific inhibitors.
• Assessed the binding of [3H]-phencyclidine to nicotinic acetylcholine receptors in the presence of imidazolines.

Main Results:

• Clonidine and cirazoline non-adrenergically inhibited nicotine-stimulated calcium influx and inward currents in PC-12 cells.
• This inhibition was independent of protein kinase activation and G-protein signaling.
• Clonidine and cirazoline displaced [3H]-phencyclidine binding, indicating interaction with the nicotinic acetylcholine receptor ion channel.

Conclusions:

• Imidazolines, specifically clonidine and cirazoline, directly block the ion channel of nicotinic acetylcholine receptors.
• This ion channel blockade represents a novel mechanism of action for these compounds.
• This finding may explain some physiological effects associated with I1 imidazoline sites, particularly in blood pressure modulation.